CTLA4 and non-small cell lung carcinoma: To further assess the impact of IC molecule inhibition promoted by BETi in the context of NK cytotoxicity, we compared the efficacy of these epigenetic drugs with monoclonal antibodies targeting different IC receptors, including PD-1 (Nivolumab), CTLA4 (Ipilimumab) or TIGIT (Vibostolimab) in our co-culture system with NSCLC cell lines and patient-derived intratumor NKs or NK92 cells (Fig. 5L, Suppl.